The perfect storm

Psychiatric Annals

Volumn 34, Issue 2, 2004, Pages 125-132

  Sabin, James E ^a   Daniels, Norman ^b   Russell Teagarden, J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CONSUMER; DEPRESSION; DRUG COST; DRUG INDUSTRY; DRUG MONITORING; DRUG PREFERENCE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MANAGED CARE ORGANIZATION; MEDICAID; MEDICAL DECISION MAKING; MEDICAL ETHICS; MENTAL HEALTH SERVICE; PATENT; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PUBLICATION; REVIEW;

EID: 2042546702     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20040201-10     Document Type: Review

References (24)

1. Teagarden JR, Daniels N, Sabin JE. The need for ethical frameworks in prescription drug benefit allocation policy. J Am Pharm Assoc (Wash). 2003;43(1):69-74.
2. Daniels N, Teagarden JR, Sabin JE. An ethical template for pharmacy benefits. Health Affairs. 2003;22(1):125-137.
3. Daniels N, Sabin JE. Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, NY: Oxford University Press; 2002.
4. Sabin JE. Managed care and health care reform: comedy, tragedy and lessons. Psychiatric Serv. 2000;51(11):1392-1396.
5. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic medical diseases. Arch Gen Psychiatry. 1995;52(1):11-19.
6. National Advisory Mental Health Council. Health care reform for Americans with severe mental illness. Am J Psychiatry. 1993;150(10):1447-1465.
7. Sabin JE, Daniels N. Ethical issues in mental health resource allocation. In: Bloch S, Chodoff P, Green SA, eds. Psychiatric Ethics. 3rd ed. Oxford, England: Oxford University Press; 1999:383-399.
8. Parens E, ed. Enhancing Human Traits: Ethical and Social Implications. Washington, DC: Georgetown University Press; 1998.
9. Glazer W, Dickson R. Pharmacoeconomics and resource allocation: lessons from North America. In: Buckley, PF, Waddington JL, eds. Schizophrenia and Mood Disorders - the New Drug Therapies in Practice. Boston, Mass: Butterowrth-Heinemann; 2000:329-343.
10. Rosenheck R, Cramer J, Allan E, et al. Cost- effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry. 1999;56(6):565-572.
11. General Accounting Office. Veterans' Healthcare: Implementation of Prescribing Guideline for Atypical Antipsychotic Drugs Generally Sound, GAO-02-579. Available at: http://www.gao.gov. Accessed December 2, 2003.
12. Levine S, Campen D, Millares M, et al. Kaiser Permanente's Prescription Drug Benefit. Health Affairs. 2000;19(2):185-190.
13. Simon GE, VonKorff M, Heiligenstein JH, et al. Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA. 1996;275(24):1897-1902.
14. Kroenke K, West SL, Gilsenan A, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947-2955.
15. Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001;286(23):3003-3004.
16. Sabin JE, Daniels N. Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs. Psychiatric Serv. 2003;54(10):1343-1344, 1349.
17. Yamhure SH. Pharmacy costs rise, management tightens - deja vu all over again? Psychiatric Practice and Managed Care. 2002;8(1):10-11.
18. Finding a path through the pharmacy maze. Psychiatric Practice and Managed Care. 2002;8(2):1,10-11.
19. Fitzpatrick C. Medication restrictions: feeling the side effects. Behav Healthc Tomorrow. 2001;10(5):14-17,39-40.
20. Formulary plan faces advocacy outcry, pharmaceutical lawsuit. Mental Health Weekly. 2001;11(47):1-3.
21. Judge blocks Michigan rollout of controversial formulary plan. Mental Health Weekly. 2002;12(2):5.
22. State MH advocates make gains against Medicaid prescription limits. Mental Health Weekly. 2002;12(26):1,4-5.
23. Sabin JE, Daniels N. Improving psychiatric drug benefit management: I. Lessons from Massachusetts. Psychiatric Serv. 2003;54(7):949-951.
24. Sabin JE, Daniels N. Strengthening the consumer voice in managed care: I. Can the private sector meet the public-sector standard? Psychiatric Serv. 2001;52(4):461-462,464.